Non-small cell lung cancer (NSCLC) patients with activating somatic mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine kinase inhibitors (TKIs) than with chemotherapy. However, even with the most effective therapies, not all patients respond. The presence of concurrent pathogenic mutations could play a role in resistance. The objective of this study was to analyze the impact of concurrent mutations in genes other than EGFR on survival outcomes of patients treated with TKIs for EGFR-mutated NSCLC.

中文翻译：

---

并发突变对EGFR突变的非小细胞肺癌总体生存的影响。

在表皮生长因子受体（EGFR）中激活了体细胞突变的非小细胞肺癌（NSCLC）患者，酪氨酸激酶抑制剂（TKIs）的疗效优于化疗。但是，即使采用最有效的疗法，也并非所有患者都会有反应。并发病原体突变的存在可能在抗性中起作用。这项研究的目的是分析EGFR以外的其他基因同时发生的突变对EGFR突变的NSCLC的TKI治疗患者生存结局的影响。